An observational study in Seminomas, sponsored by Centre Hospitalier Universitaire Dijon. Status unknown at 1 site in France. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-25.
Sponsored by Centre Hospitalier Universitaire Dijon · Observational
Recent data suggest that sperm cells carry an epigenetic message during spermatogenesis and that this message is crucial for the future development of the embryo. This epigenetic signature is notably represented by methylation of genes subjected to imprinting (GSI) and the methylation of transposable elements (TE). Data on the maintenance of the imprint and of the control of TE accompanying human gametogenesis in a context of adult germinal testicular cancers, seminomas, are extremely fragmentary for tumour tissues and inexistent for gametes.
The aim of this study is to determine whether patients with seminomas in comparison with fertile men carry a higher risk of presenting epigenetic alterations affecting their gametes.
This study is based on the use of an existing collection of biological samples. 90 samples will be selected and split into 3 groups:
After treatment of the samples (thawing, cell sorting and removal of cryoprotectants), they will be analysed.
seminomas
Exclusion Criteria:
Other: Extraction genomic DNA · Other: Analysis of methylation profiles of numerous GSI and TE · Other: Analysis of methylation for the whole genome (sub-population of 15 samples from group 1) · Other: Method of protein detection by immunostaining and flow cytometry
Other: Extraction genomic DNA · Other: Analysis of methylation profiles of numerous GSI and TE · Other: Method of protein detection by immunostaining and flow cytometry
Other: Extraction genomic DNA · Other: Analysis of methylation profiles of numerous GSI and TE · Other: Method of protein detection by immunostaining and flow cytometry
Analysis of methylation profiles in paternal genes subjected to imprinting (GSI)
Time frame: at baseline
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Dijon